Gyre Therapeutics, Inc. GYRE Change In Fair Value Of Long Term Receivables
Change In Fair Value Of Long Term Receivables at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept gyre:ChangeInFairValueOfLongTermReceivables.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s change in fair value of long term receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s change in fair value of long term receivables?
- Gyre Therapeutics, Inc. (GYRE) reported change in fair value of long term receivables of $39K in Q1 2025.
- How has Gyre Therapeutics, Inc.'s change in fair value of long term receivables changed year-over-year?
- Gyre Therapeutics, Inc.'s change in fair value of long term receivables decreased by 32.8% year-over-year, from $58K to $39K.
- What does change in fair value of long term receivables mean?
- Measures the periodic adjustment to the carrying value of long-term receivables based on market conditions or credit risk assessments. This non-cash item reflects changes in the estimated future value of assets owed to the company. It is critical for understanding the volatility of long-term asset valuations.